Skip to main content
    E

    Enliven Therapeutics Inc. (ELVN)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $47.62
    -1.18 (-2.42%)

    Market Cap: $3.59B

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Enliven Therapeutics Inc. (ELVN) Earnings: Report Dates and Results

    Updated Nov 5, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Enliven Therapeutics (ELVN) is expected to report earnings on Mar 1, 2027. In the quarter ended Sep 30, 2026, Enliven Therapeutics reported EPS of -$0.36, above the -$0.48 estimate. It beat the EPS estimate in 4 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    67%(18/27)
    Avg Surprise
    -2.78%
    Streak
    1 Q

    Upcoming Estimates

    Reports Mar 1, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus-$0.53
    Range-$0.68 - -$0.42
    16 analysts
    Revenue Consensus
    N/A
    RangeN/A
    11 analysts
    Reports May 5, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus-$0.46
    Range-$0.54 - -$0.42
    5 analysts
    EPS RevisionsNo revisions (30d)
    EPS Estimate DriftChange to current
    90d ago-$0.54+14.1%
    60d ago-$0.53+12.5%
    30d ago-$0.54+14.1%
    7d ago-$0.53+12.1%
    Current-$0.46
    Revenue Consensus
    N/A
    RangeN/A
    2 analysts

    Next Report

    ELVN has an expected report date of Mar 1, 2027.

    Earnings History

    Of the 27 quarters below that had an estimate, ELVN beat 18 and missed 9. The widest gap in the table came in the quarter ended Mar 31, 2020, when EPS landed 486.39% below the estimate.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReported
    Sep 30, 2026-$0.36-$0.48-$0.52 - -$0.38+25.00%BeatN/A80 up, 2 downNov 5, 2026
    Jun 30, 2026-$0.49-$0.38-$0.40 - -$0.29-28.95%MissN/A3N/AAug 5, 2026
    Mar 31, 2026-$0.38-$0.41-$0.51 - -$0.31+7.32%BeatN/A20 up, 0 downMay 7, 2026
    Dec 31, 2025-$0.48-$0.38N/A-27.05%MissN/A20 up, 0 downMar 3, 2026
    Sep 30, 2025-$0.32-$0.46-$0.48 - -$0.45+30.43%BeatN/A20 up, 0 downNov 12, 2025
    Jun 30, 2025-$0.49-$0.42-$0.47 - -$0.37-16.67%MissN/A20 up, 0 downAug 13, 2025
    Mar 31, 2025-$0.57-$0.50N/A-14.00%MissN/AN/A0 up, 0 downMay 14, 2025
    Dec 31, 2024-$0.46-$0.52N/A+11.11%BeatN/AN/A0 up, 0 downMar 13, 2025
    Sep 30, 2024-$0.48-$0.50-$0.55 - -$0.44+4.00%BeatN/A80 up, 0 downNov 13, 2024
    Jun 30, 2024-$0.41-$0.56-$0.65 - -$0.49+26.79%BeatN/A60 up, 0 downAug 13, 2024
    Mar 31, 2024-$0.54-$0.57-$0.58 - -$0.55+5.26%BeatN/A30 up, 0 downMay 14, 2024
    Dec 31, 2023-$0.47-$0.54-$0.56 - -$0.51+12.96%Beat-138.8%40 up, 0 downMar 14, 2024
    Sep 30, 2023-$0.51-$0.47-$0.53 - -$0.44-8.51%MissN/A30 up, 0 downNov 9, 2023
    Jun 30, 2023-$0.41-$0.40N/A-2.50%MissN/AN/AN/AAug 10, 2023
    Mar 31, 2023-$0.80-$0.52N/A-53.85%MissN/AN/AN/AMay 11, 2023
    Dec 31, 2022$1.21-$0.79N/A+253.94%BeatN/AN/AN/AFeb 10, 2023
    Sep 30, 2022-$0.72-$1.00N/A+28.00%BeatN/AN/AN/AOct 25, 2022
    Jun 30, 2022-$1.76-$2.05N/A+14.15%BeatN/AN/AN/AAug 3, 2022
    Mar 31, 2022-$2.24-$2.31N/A+3.03%BeatN/AN/AN/AMay 6, 2022
    Dec 31, 2021-$2.12-$3.00N/A+29.33%BeatN/AN/AN/AMar 15, 2022
    Sep 30, 2021-$2.20-$3.38N/A+34.91%BeatN/AN/AN/ANov 9, 2021
    Jun 30, 2021-$2.96-$3.20N/A+7.50%BeatN/AN/AN/AAug 6, 2021
    Mar 31, 2021-$2.32-$3.34N/A+30.54%BeatN/AN/AN/AMay 11, 2021
    Dec 31, 2020-$2.24-$3.35N/A+33.13%BeatN/AN/AN/AMar 5, 2021
    Sep 30, 2020-$2.88-$3.21N/A+10.28%BeatN/AN/AN/ANov 5, 2020
    Jun 30, 2020-$2.36-$2.25N/A-4.89%MissN/AN/AN/AAug 14, 2020
    Mar 31, 2020-$17.24-$2.94N/A-486.39%MissN/AN/AN/AMay 7, 2020
    Dec 31, 2019-$0.68N/AN/AN/AN/AN/AN/AN/AMar 11, 2020
    Sep 30, 2019-$0.32N/AN/AN/AN/AN/AN/AN/AOct 8, 2019
    Last 29 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$1.86, after -$1.89 the year before. It was -$1.00 for the year ended Dec 31, 2019, the oldest of the 7 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$1.86N/A
    Dec 31, 2024-$1.89N/A
    Dec 31, 2023-$2.19N/A
    Dec 31, 2022-$3.51N/A
    Dec 31, 2021-$9.60N/A
    Dec 31, 2020-$24.72N/A
    Dec 31, 2019-$1.00N/A

    Frequently Asked Questions About ELVN

    When is Enliven Therapeutics's next earnings date?

    Enliven Therapeutics's next earnings report is expected for Mar 1, 2027.

    Did ELVN beat earnings estimates last quarter?

    Yes. Enliven Therapeutics reported EPS of -$0.36 for the quarter ended Sep 30, 2026, above the -$0.48 estimate, a 25.00% surprise.

    What EPS do analysts expect from ELVN next quarter?

    The consensus EPS estimate for Enliven Therapeutics for the quarter ending Dec 31, 2026 is -$0.53 from 16 analysts, with estimates from -$0.68 to -$0.42.

    How often does ELVN beat earnings estimates?

    Enliven Therapeutics beat the EPS estimate in 4 of the last 8 quarters, with an average surprise of -1.60%.